Cowen believes UnitedHealth is well positioned across all business lines with the exception of prescription drug plans and individual health insurance. The firm expects strong government enrollment in 2016 and 2017 while Optum remains a key earnings driver and said Medicare Advantage margins could be a potential source of upside. Cowen reiterated its Outperform rating and $140 price target on UnitedHealth shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here